Press

Wesana Health Holdings Inc. (CSE: WESA), a data-driven life sciences company, announced today that the Company’s Wesana Clinics business segment has surpassed 4,000 administered ketamine treatments for major depressive disorder, anxiety, PTSD, and addiction since inception. “This is a significant achievement for Wesana Clinics. There is an urgent need for innovative and effective treatments to combat the current budding epidemics of suicide, addiction, anxiety, and depression. We continue to believe that Wesana’s clinical network remains at the forefront of mental health advancements while maintaining a strong foundation in traditional psychiatric care.” Daniel Carcillo, CEO of Wesana Health Wesana’s psychiatrist-led clinical…

Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has received correspondence from the U.S. Food and Drug Administration related to the Company’s Investigational New Drug application for a clinical study in overeating disorders. The FDA has requested certain changes to the protocol of the upcoming study, and Tryp will be modifying the protocol to incorporate all of the FDA’s requests. The primary changes include the following: Focusing enrollment of the initial phase 2a study on patients with binge eating disorder Submitting an IND for a separate phase…

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that it has entered into a co-development and exclusive licensing agreement with EntheoTech Bioscience Inc., a bioscience company focused on the research and development of formulas and protocols to support opioid tapering and treat chronic pain, depression and other mental health conditions. Under the agreement, Filament will exclusively license its botanical psilocybin drug candidate, PEX010, to EntheoTech for two upcoming clinical trials addressing opioid use for chronic pain and depression. Separately, Filament will co-develop psychedelic drug candidates derived from mushrooms grown from EntheoTech’s…

Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod® transdermal technology. “The commencement of Novel Ketamine loaded Z-Pods  is a pivotal advancement for administering Ketamine as a therapeutic with the patented Z-Pod® technology.  This important milestone for Silo will help us study the benefits of slow-release transdermal release of Ketamine.  The delivery and loading accelerates the development to deliver Ketamine as a therapeutic and potentially Psilocybin in a time-released or dosage-controlled manner.”…

MindMed (Nasdaq: MNMD), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended September 30, 2021. Third Quarter 2021 Financial Highlights (in USD) Cash Balance. Total assets as of September 30, 2021 were $178.6 million, including $145.9 million in cash, as compared to $85.6 million, including $80.1 million in cash, as of December 31, 2020 Net Cash Used in Operating Activities. Net Cash Used in Operating Activities of $10.8 million and $31.9 million for the three and nine months ended September 30, 2021, as compared to $5.8 million and $16.5 million for the three and nine months ended September 30, 2020, respectively Net Loss. Net and comprehensive loss of $24.3 million and $74.6 million for the three and nine months…